Swedish Orphan Biovitrum
Clinical trials sponsored by Swedish Orphan Biovitrum, explained in plain language.
A biopharmaceutical company focused on rare diseases, now part of Sobi.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for myelofibrosis patients with dangerous low platelet counts Results expected Oct 2026 (estimated)
- Weekly shot may shield joints in hemophilia a patients Results expected Nov 2026 (estimated)
- New hope for rare inflammatory disease: pacritinib trial begins Results expected Dec 2026 (estimated)
- Real-World data may unlock Pacritinib's true potential in myelofibrosis Results expected Jan 2027 (estimated)
- New clotting factor offers continued bleeding control for hemophilia a patients Results expected Mar 2027 (estimated)
-
New hope for rare inflammatory disease: pacritinib trial begins
Disease control OngoingThis study tests a drug called pacritinib for people with VEXAS syndrome, a rare genetic disease that causes severe inflammation. About 78 adults will receive either the drug or a placebo to see if it controls symptoms and reduces flare-ups. The goal is to find a safe and effecti…
Phase 2 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Real-World test: can a targeted drug keep PNH in check for years?
Disease control OngoingThis study follows about 200 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking pegcetacoplan (Aspaveli/Empaveli) as part of their routine care. Researchers will track blood markers, symptoms, and side effects for up to 3 years to see how well the drug works out…
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could a daily injection tame two rare inflammatory diseases?
Disease control CancelledThis study tests the drug anakinra in Chinese patients with two related inflammatory conditions: Systemic Juvenile Idiopathic Arthritis (SJIA) in children and Adult-Onset Still's Disease (AOSD) in adults. Participants receive a daily injection under the skin for 48 weeks. The goa…
Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for rare fever disorder: drug targets stubborn cases
Disease control CancelledThis study tests whether anakinra (Kineret), a daily injection, can reduce monthly attacks in Chinese patients with Familial Mediterranean Fever (FMF) who do not respond to standard colchicine treatment. Three patients aged 2 years and older will receive anakinra for 6 months, wi…
Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Weekly shot may shield joints in hemophilia a patients
Disease control OngoingThis study tests whether a once-weekly medication (efanesoctocog alfa) can improve or prevent joint damage in 37 people with moderate or severe hemophilia A. Participants receive the drug for 12 months, and doctors use ultrasound and MRI to check joint health. The goal is to see …
Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for myelofibrosis patients with dangerous low platelet counts
Disease control OngoingThis phase 3 study tests a drug called pacritinib against standard treatments chosen by the doctor in people with myelofibrosis who have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and reduce symptoms like tiredness, pain, and i…
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New study tracks Elocta's Long-Term joint protection in hemophilia
Disease control OngoingThis 48-month study observes 427 people with hemophilia A who are already using Elocta to prevent bleeding. Researchers want to see how well the drug protects joints over time, including how many joint bleeds occur and whether target joints improve or worsen. The goal is to under…
Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
HT-1 drug study in china withdrawn before starting
Knowledge-focused CancelledThis study was designed to observe how patients with hereditary tyrosinemia type 1 (HT-1) in China respond to nitisinone treatment in everyday medical practice. It planned to track serious health events like liver problems or death. However, the study was withdrawn before enrolli…
Sponsor: Swedish Orphan Biovitrum • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC